Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Kalaris Therapeutics Inc. (KLRS) had Stock-Based Compensation of $1.22M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-11.52M |
|
-- |
|
-- |
|
$12.39M |
|
$-12.39M |
|
$0.87M |
|
$-11.52M |
|
$-11.52M |
|
$-11.52M |
|
$-11.52M |
|
$-11.52M |
|
$-11.52M |
|
$-12.39M |
|
$-12.49M |
|
23.80M |
|
23.80M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$95.92M |
|
-- |
|
$3.62M |
|
$99.54M |
|
$8.74M |
|
-- |
|
$33.13M |
|
$41.87M |
|
$57.67M |
|
$57.67M |
|
$57.67M |
|
23.80M |
|
| Cash Flow Statement Financials | |
$-22.63M |
|
$-30.18M |
|
$-2.07M |
|
$98.55M |
|
$43.67M |
|
$-54.88M |
|
|
Stock-Based Compensation |
$1.22M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.98 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-22.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.97% |
|
-19.97% |
|
-11.57% |
|
-19.97% |
|
$2.42 |
|
$-0.95 |
|
$-0.95 |
|